carv
lower
respiratori
tract
diseas
lrtd
concurr
pulmonari
coinfect
set
allogen
hematopoiet
stem
cell
transplant
allohsct
scarc
januari
decemb
retrospect
compar
outcom
allohsct
recipi
diagnos
carv
lrtd
monoinfect
n
group
viral
bacteri
fungal
pulmonari
carv
lrtd
coinfect
n
group
n
group
n
group
respect
bacteri
pneumonia
monoinfect
n
group
overal
surviv
os
day
bronchoalveolar
lavag
bal
significantli
higher
group
compar
group
vs
respect
p
recipi
group
show
trend
better
os
compar
group
vs
p
multivari
analys
show
bacteri
coinfect
rf
mortal
hazard
ratio
hr
ci
p
identifi
rf
mortal
lymphocyt
count
l
hr
p
occurr
cmv
dnaemia
requir
antivir
therapi
cmvdnaemiarat
time
bal
hr
ci
p
need
oxygen
support
hr
ci
p
carv
lrtd
coinfect
frequent
may
neg
effect
outcom
particular
context
bacteri
coinfect
allogen
hematopoiet
stem
cell
transplant
cmv
dnaemia
commun
acquir
respiratori
viru
immunodefici
score
index
respiratori
viru
coinfect
virusbacteri
mix
infect
communityacquir
respiratori
virus
carv
common
caus
upper
andor
lower
respiratori
tract
infect
urti
lrtd
allogen
stem
cell
transplant
allohsct
result
high
morbid
mortal
especi
lower
respiratori
tract
involv
recent
introduct
daili
clinic
practic
sophist
diagnost
tool
base
revers
transcript
polymeras
chain
reaction
rtpcr
test
carv
pathogen
permit
expand
microbiolog
find
bronchoalveolar
lavag
bal
allohsct
recipi
harbor
lower
respiratori
tract
lrt
complic
fact
like
increas
abil
diagnos
infecti
pneumonia
probabl
led
identif
high
number
case
copathogen
compar
convent
microbiolog
studi
ie
viral
cultur
antigen
test
avail
carv
current
lack
studi
analyz
detail
incid
charact
purpos
studi
analyz
clinic
implic
coinfect
viral
fungal
bacteri
carv
lrtd
coinfect
detect
bal
sampl
cohort
allohsct
recipi
firstproven
carv
lrtd
episod
compar
outcom
monoinfect
carv
bacteri
lrt
monoinfect
addit
analyz
risk
factor
rf
valu
immunodefici
score
index
isi
predict
morbid
mortal
allohsct
recipi
carv
lrtd
rtpcr
era
variabl
immunodefici
score
index
isi
variabl
respect
hsct
month
tcell
bcell
deplet
month
graft
versushost
diseas
gvhd
grade
extens
diseas
neutropenia
x
l
lymphopenia
x
l
microbiolog
find
bal
sampl
radiolog
pattern
also
collect
critic
review
local
ethic
committe
approv
studi
avail
subject
gave
written
inform
consent
particip
studi
bronchoscopi
perform
use
standard
procedur
accord
intern
consensu
guidelin
origin
basel
immunodefici
grade
score
also
includ
immunoglobulin
g
level
igg
gl
adapt
basel
ig
sinc
immunoglobulin
g
level
avail
time
bal
patient
quantit
cultur
bal
specimen
bacteri
isol
perform
convent
media
recommend
agreement
gener
accept
threshold
cmv
dna
plasma
quantifi
use
realtim
cmv
pcr
assay
abbott
molecular
de
plain
il
usa
exhibit
limit
detect
approxim
iuml
hcuv
previous
describ
hlf
cmv
biomerieux
letoil
pari
franc
display
limit
detect
iuml
perform
surveil
cmv
dnaemia
quantit
conduct
least
week
within
first
day
allohsct
outpati
visit
immunosuppress
center
preemptiv
antivir
therapi
approach
use
hcuv
prevent
cmv
endorgan
diseas
patient
preemptiv
cmv
dnaemiarat
defin
describ
acut
graft
versu
host
diseas
agvhd
diagnos
grade
accord
standard
criteria
enterococcu
faecali
e
faecium
consid
put
causat
bacteri
pneumonia
pathogenet
signific
bacteria
identifi
bal
sampl
term
mix
flora
use
yeast
belong
candida
spp
consid
coinfect
agent
contrast
probableproven
pulmonari
ia
diagnos
time
carv
lrtd
consid
fungal
coinfect
detect
cmv
dna
bal
rtpcr
consid
copathogen
entiti
studi
sinc
quit
common
phenomenon
interpret
still
uncertain
allohsct
recipi
receiv
broadspectrum
antibiot
carbapenem
cefepim
piperacillinetazobactam
case
hemodynam
instabl
akimacin
ad
time
microbiolog
result
antimicrobi
therapi
adapt
accordingli
primari
object
studi
describ
clinic
clinic
biolog
characterist
carv
lrtd
shown
tabl
common
type
carv
detect
evrh
case
follow
rsv
hpiv
influenza
hmpv
adv
cov
case
seventyfour
carv
lrtd
occur
within
first
year
allohsct
twentytwo
case
occur
day
stem
cell
infus
develop
lrtd
day
day
day
year
observ
signific
clinic
andor
biolog
differ
among
group
except
lower
rate
cmv
dnaemiarat
group
p
univari
multivari
analys
rf
carv
lrtd
bacterialviru
coinfect
day
caus
mortal
shown
tabl
respect
p
figur
gramneg
bacteria
p
case
respect
found
mix
flora
bal
icu
admiss
rate
p
mortal
rate
group
respect
p
day
os
higher
group
compar
group
although
signific
reach
figur
limit
analysi
recipi
gramneg
bacteria
observ
recipi
group
die
day
bal
compar
group
p
studi
herein
show
carv
lrtd
coinfect
common
allohsct
bacteri
pneumonia
coinfect
recipi
carv
lrtd
associ
increas
mortal
also
nucleic
acid
amplif
test
report
high
rate
carv
lrtd
coinfect
consid
respiratori
viru
ia
signific
bacteri
coinfect
prior
studi
rtpcr
era
report
lower
coinfect
rate
bal
sampl
fact
limit
knowledg
regard
role
coinfect
clinic
outcom
carv
lrtd
studi
report
pool
coinfect
bacteremia
fungal
infect
cmv
reactiv
herp
simplex
viru
human
herpesviru
epsteinbarr
viru
significantli
increas
mortal
allohsct
recipi
sever
carv
type
other
fail
demonstr
neg
effect
report
lack
comparison
monoinfect
counterpart
studi
provid
evid
carv
lrtd
bacteri
coinfect
display
neg
effect
mortal
multivari
analysi
interestingli
observ
trend
poorer
outcom
recipi
carv
lrtd
bacteri
coinfect
compar
bacteri
pneumonia
monoinfect
find
suggest
neg
effect
bacteri
coinfect
seem
independ
explain
predomin
influenc
bacteri
agent
rather
coinfect
statu
limit
analysi
gramneg
bacilli
also
observ
higher
mortal
carv
lrtd
gramneg
bacteri
coinfect
compar
gramneg
bacteri
pneumonia
monoinfect
although
signific
reach
probabl
due
low
number
recipi
includ
anoth
relev
find
studi
identif
rf
mortal
easili
identifi
time
carv
lrtd
rf
alreadi
identifi
prognost
marker
progress
lrtd
ie
lymphopenia
sever
studi
among
differ
respiratori
viru
rf
mortal
ie
lymphopenia
oxygen
requir
cmv
dnaemiarat
rf
built
risk
score
abl
discrimin
group
differ
risk
mortal
irrespect
coinfect
statu
merit
valid
studi
contrast
abl
provid
evid
clinic
use
neither
isi
score
adapt
basel
immunodefici
grade
score
predict
mortal
multivari
analysi
pool
carv
lrtd
cohort
although
isi
origin
design
rsv
valid
influenza
viru
like
coinfect
includ
isi
hamper
abil
predict
outcom
seri
fact
none
variabl
includ
isi
statist
signific
uniand
multivari
model
reflect
weak
model
cohort
fact
suggest
valid
isi
carv
warrant
routin
applic
therapeut
decisionmak
regard
basel
immunodefci
grade
score
fact
includ
immunoglobulin
levelsin
score
may
hamper
abil
assess
true
valu
valid
would
requir
regard
analysi
rf
coinfect
carv
lrtd
decis
limit
analysi
bacteri
coinfect
justifi
main
reason
first
studi
show
bac
carv
lrtd
coinfect
acknowledg
studi
limit
includ
rel
low
number
patient
use
differ
multiplex
pcr
platform
carv
inclus
sever
carv
type
well
retrospect
natur
addit
multipl
virus
detect
abl
differenti
author
declar
conflict
interest
